However, the pre-hAMSC group exhibited better maintenance of post-MI LV systolic function on a long-term basis, which presumably originates from the enhancement of anti-fibrosis and immunomodulatory properties with S100A8/A9 pretreatment demonstrated in the in vitro experiments (Figure 3 and Figure 5C). This evidence concerns the gene S100A8 and myocardial infarction.